UY27565A1 - Combinación farmacéutica. - Google Patents

Combinación farmacéutica.

Info

Publication number
UY27565A1
UY27565A1 UY27565A UY27565A UY27565A1 UY 27565 A1 UY27565 A1 UY 27565A1 UY 27565 A UY27565 A UY 27565A UY 27565 A UY27565 A UY 27565A UY 27565 A1 UY27565 A1 UY 27565A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical combination
receptor agonist
combination
adenosine
inhaled
Prior art date
Application number
UY27565A
Other languages
English (en)
Inventor
Michael Yeadon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY27565A1 publication Critical patent/UY27565A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una combinación que comprende (A) un agonista del receptor de adenosina A2a como se define en la presente memoria y (b) un agonista del receptor B2- adrenérgico, para la administración simultánea, secuencial o por separado por vía inhalada en el tratamiento de una enfermedad obstructiva de las vías respiratorias u otra enfermedad inflamatoria.
UY27565A 2001-12-07 2002-12-05 Combinación farmacéutica. UY27565A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0129397.6A GB0129397D0 (en) 2001-12-07 2001-12-07 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
UY27565A1 true UY27565A1 (es) 2003-07-31

Family

ID=9927249

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27565A UY27565A1 (es) 2001-12-07 2002-12-05 Combinación farmacéutica.

Country Status (12)

Country Link
US (1) US20030109485A1 (es)
AR (1) AR037709A1 (es)
AU (1) AU2002347532A1 (es)
GB (1) GB0129397D0 (es)
GT (1) GT200200261A (es)
HN (1) HN2002000355A (es)
PA (1) PA8560401A1 (es)
PE (1) PE20030835A1 (es)
SV (1) SV2004001429A (es)
TW (1) TW200303754A (es)
UY (1) UY27565A1 (es)
WO (1) WO2003047628A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455437B2 (en) * 2005-02-04 2013-06-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method to predict and prevent oxygen-induced inflammatory tissue injury
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
JP2016518388A (ja) 2013-04-30 2016-06-23 オティトピック インク． 乾燥粉末配合および使用方法
JP7493449B2 (ja) 2017-09-22 2024-05-31 ヴェクチュラ インコーポレイテッド ステアリン酸マグネシウムを含む乾燥粉末組成物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1142798C (zh) * 1995-04-14 2004-03-24 葛兰素惠尔康公司 沙美特罗的计定剂量吸入器
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives

Also Published As

Publication number Publication date
TW200303754A (en) 2003-09-16
AU2002347532A1 (en) 2003-06-17
AR037709A1 (es) 2004-12-01
PE20030835A1 (es) 2003-10-08
US20030109485A1 (en) 2003-06-12
GB0129397D0 (en) 2002-01-30
SV2004001429A (es) 2004-05-07
GT200200261A (es) 2003-07-11
WO2003047628A1 (en) 2003-06-12
HN2002000355A (es) 2003-02-21
PA8560401A1 (es) 2003-12-10

Similar Documents

Publication Publication Date Title
SV2003001055A (es) Un agonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias areas
CL2008002207A1 (es) Composicion farmaceutica que comprende inmunosupresores para la mejora del efecto en el uso de un antagonista de interleucina-6 (il-6) para el tratamiento de enfermedades relacionadas con il-6 (div. sol. 896-04).
ECSP034571A (es) Nuevas composiciones de medicamentos a base de sales de tiotropio y sales del salmeterol
CY1106430T1 (el) Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
WO2006124681A3 (en) Oral drug delivery system and methods of use thereof
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
CY1113482T1 (el) Αναστολεις υποδοχεα σιγμα
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR034223A1 (es) Novedosa indicacion terapeutica de azitromicina para el tratamiento de enfermedades inflamatorias no infecciosas
CY1113404T1 (el) Μεθοδος αντιμετωπισης ή προληψης της πολυ- οργανικης ανεπαρκειας
ECSP045132A (es) Combinacion farmaceutica
DK1401405T3 (da) Orale, farmaceutiske sammensætninger med forbedret biotilgængelighed
UY27565A1 (es) Combinación farmacéutica.
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
CY1105548T1 (el) Συνδυασμος του loteprednol και αγωνιστων του β2-αδρενοϋποδοχεως και η χρηση του με εισπνοες για την αγωγη του βρογχικου ασθματος
DE602005010844D1 (de) Pharmazeutische zusammensetzungen mit interferon-tau
BRPI0418764B8 (pt) uso de espinosina, ou de um derivado ou sal fisiologicamente aceitável da mesma, na preparação de medicamentos para promover ou acelerar a cura de ferimento em um ser humano
DOP2002000514A (es) Combinacion farmaceutica.
ECSP045142A (es) Combinacion farmaceutica
UY27670A1 (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinérgicos y de agentes inhibidores de la cinasa del egfr
AR036679A1 (es) Formulaciones y uso de las mismas
DOP2002000523A (es) Combinacion farmaceutica.
UY27308A1 (es) Un agonista de a2a en combinación con un agente anticolinérgico para el tratamiento de enfermedades obstructivas de las vias aéreas
ECSP034863A (es) Un agonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126